Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Postprint
DOI
PMC
 |
Open Access Green |
as soon as is submitted to ZB.
Novel viral and host targets to cure hepatitis B.
Curr. Opin. Virol. 24, 38-45 (2017)
Hepatitis B virus (HBV) infection is a global health threat with 240 million chronic carriers at high risk to develop hepatocellular carcinoma. Current antiviral treatment can efficiently control viral replication and reduce liver inflammation, but is still quite far from achieving a cure. Significant progress has been made in understanding the virus life cycle and virus-host interaction in the past few years. With identification of the HBV receptor, cell-culture infection systems have become available that allow drug screening and establishing a pipeline of potential antivirals targeting either viral or host factors. Most of the candidate antivirals summarized in this review are still in preclinical development, but some have already entered or are about to enter early clinical trials.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Virus X Protein; Nonhepatotoxic Degradation; Hepatocellular-carcinoma; Reverse-transcriptase; Restriction Factor; Gene-expression; Cccdna Function; Analog Therapy; Reduced Risk; Hbx Protein
ISSN (print) / ISBN
1879-6257
e-ISSN
1879-6265
Journal
Current Opinion in Virology
Quellenangaben
Volume: 24,
Pages: 38-45
Publisher
Elsevier
Publishing Place
Oxford
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Virology (VIRO)